Vyome Stands Out Among Surgical Instrument Rivals

Vyome's strong financials and institutional backing give it an edge over competitors in the medical devices industry.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Vyome (NASDAQ:HIND), a publicly-traded company in the 'Surgical, Medical, And Dental Instruments And Supplies' industry, has been compared to its 26 rivals. The analysis shows that while Vyome's rivals have higher revenue, Vyome has stronger earnings per share and a lower price-to-earnings ratio, indicating it is more affordable than competitors. Vyome also has a stronger consensus rating from analysts and higher potential upside compared to the industry average. Additionally, Vyome has greater institutional and insider ownership, suggesting strong backing from major investors.

Why it matters

This analysis provides insight into Vyome's competitive position within the medical devices industry. Vyome's favorable financial metrics, analyst sentiment, and ownership structure suggest it may be poised for outperformance relative to its peers, which could be of interest to investors looking for opportunities in this sector.

The details

The key findings of the analysis are: Vyome has lower revenue but higher earnings per share than its rivals; Vyome trades at a lower price-to-earnings ratio, making it more affordable; Vyome has a stronger consensus rating from analysts and higher potential upside; Vyome has greater institutional and insider ownership, indicating strong backing from major investors; and Vyome has lower share price volatility compared to the industry average.

  • The analysis was published on March 9, 2026.

The players

Vyome

A publicly-traded company in the 'Surgical, Medical, And Dental Instruments And Supplies' industry.

ReShape Lifesciences Inc.

A medical device company that provides products and services to manage and treat obesity and metabolic diseases.

Got photos? Submit your photos here. ›

The takeaway

Vyome's strong financial performance, positive analyst sentiment, and robust institutional and insider ownership suggest it may be a compelling investment opportunity in the medical devices industry, outpacing its competitors on several key metrics.